Brand Name | Status | Last Update |
---|---|---|
acid reducer | ANDA | 2024-02-15 |
basic care esomeprazole magnesium | ANDA | 2024-07-25 |
berkley and jensen heartburn treatment | ANDA | 2024-07-31 |
careone esomeprazole magnesium | ANDA | 2019-12-18 |
dg health esomeprazole magnesium | ANDA | 2024-08-02 |
equaline esomeprazole magnesium | ANDA | 2024-08-01 |
esomeprazole | ANDA | 2023-11-03 |
esomeprazole dr | ANDA | 2023-08-23 |
esomeprazole magnesium | ANDA | 2024-10-23 |
esomeprazole magnesium delayed-release 20 mg mini esomeprazole magnesium delayed-release capsules, 20 mg | ANDA | 2024-03-18 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | 9 | 19 | 30 | 36 | 24 | 115 |
Infections | D007239 | EFO_0000544 | — | 2 | 5 | 9 | 61 | 33 | 107 |
Healthy volunteers/patients | — | — | — | 56 | 1 | 1 | 6 | 2 | 65 |
Helicobacter infections | D016481 | EFO_1000961 | — | 2 | 5 | 9 | 25 | 19 | 57 |
Peptic esophagitis | D004942 | EFO_1001095 | — | 1 | 7 | 14 | 8 | 10 | 39 |
Ulcer | D014456 | MPATH_579 | — | 2 | 2 | 17 | 10 | 6 | 37 |
Communicable diseases | D003141 | — | — | 1 | 3 | 4 | 15 | 13 | 34 |
Gastritis | D005756 | EFO_0000217 | K29.7 | 3 | 1 | 5 | 17 | 6 | 32 |
Esophagitis | D004941 | HP_0100633 | K20 | 2 | 8 | 12 | 6 | 4 | 31 |
Peptic ulcer | D010437 | HP_0004398 | K27 | 3 | 1 | 4 | 16 | 6 | 30 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Duodenal ulcer | D004381 | EFO_0004607 | K26 | 1 | — | 5 | — | 5 | 11 |
Eosinophilic esophagitis | D057765 | EFO_0004232 | K20.0 | — | 2 | 1 | — | 1 | 3 |
Asthma | D001249 | EFO_0000270 | J45 | — | 2 | 1 | — | — | 3 |
Esophageal neoplasms | D004938 | — | C15 | — | 1 | 1 | — | — | 2 |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | 1 | — | 1 | 2 |
Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | 1 | — | 1 | 2 |
Recurrence | D012008 | — | — | — | 1 | 1 | — | 1 | 2 |
Gastrinoma | D015408 | — | — | — | — | 1 | — | 1 | 2 |
Zollinger-ellison syndrome | D015043 | — | E16.4 | — | — | 1 | — | 1 | 2 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 2 |
Autism spectrum disorder | D000067877 | HP_0000729 | F84.0 | 1 | 1 | — | — | — | 2 |
Head and neck neoplasms | D006258 | — | — | — | 1 | — | — | 1 | 2 |
Replacement arthroplasty knee | D019645 | — | — | — | 1 | — | — | — | 1 |
Neuralgia | D009437 | EFO_0009430 | — | — | 1 | — | — | — | 1 |
Chronic pain | D059350 | HP_0012532 | — | — | 1 | — | — | — | 1 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 1 | — | — | — | 1 |
Autistic disorder | D001321 | HP_0000717 | F84.0 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 4 | — | — | — | 1 | 5 |
Therapeutic equivalency | D013810 | — | — | 4 | — | — | — | — | 4 |
Pharmacological phenomena | D000069437 | — | — | 2 | — | — | — | — | 2 |
Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | — | 1 |
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 1 | — | — | — | — | 1 |
Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | — | 1 |
Hepatitis b | D006509 | — | — | 1 | — | — | — | — | 1 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | — | — | — | — | 1 |
Hyperplasia | D006965 | EFO_0000536 | — | 1 | — | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 4 | 4 |
Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 2 | 2 |
Gastrointestinal microbiome | D000069196 | — | — | — | — | — | — | 2 | 2 |
Shoulder injuries | D000070599 | — | — | — | — | — | — | 1 | 1 |
Drug interactions | D004347 | — | — | — | — | — | — | 1 | 1 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | — | — | — | 1 | 1 |
Pyloromyotomy | D000074882 | — | — | — | — | — | — | 1 | 1 |
Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 1 | 1 |
Calcium metabolism disorders | D002128 | EFO_0005769 | E83.5 | — | — | — | — | 1 | 1 |
Knee osteoarthritis | D020370 | EFO_0004616 | M17 | — | — | — | — | 1 | 1 |
Drug common name | Esomeprazole strontium |
INN | esomeprazole |
Description | Nexium Control (esomeprazole strontium) is a small molecule pharmaceutical. Esomeprazole strontium was first approved as Esomeprazole strontium on 2013-08-06. It is used to treat duodenal ulcer, esophagitis, gastroesophageal reflux, heartburn, and helicobacter infections amongst others in the USA. It has been approved in Europe to treat gastroesophageal reflux. |
Classification | Small molecule |
Drug class | antiulcer agents (benzimidazole derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.COc1ccc2[n-]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1.O.O.O.O.[Sr+2] |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL2146140 |
ChEBI ID | — |
PubChem CID | 16048656 |
DrugBank | — |
UNII ID | N3PA6559FT (ChemIDplus, GSRS) |